Evidence‑Based Practices for ICU Antibiotic Stewardship

Immediate Empiric Therapy

• Administer intravenous antibiotics within the first hour of recognizing sepsis or septic shock; each hour of delay is associated with increased mortality in critically ill patients. 1
• Obtain blood cultures before starting antibiotics, but never postpone antimicrobial administration to wait for specimen collection. 1
• Collect site‑specific specimens for hospital‑acquired infections, prior antibiotic exposure, or known multidrug‑resistant colonization, without delaying therapy. 1

Criteria for Empiric Antibiotic Selection

• Choose initial regimens based on (1) local ICU epidemiology and resistance patterns, (2) individual patient risk factors for multidrug‑resistant (MDR) pathogens, (3) severity of illness, and (4) the presumed infection source. 2
• Prior antibiotic exposure is the strongest patient‑level risk factor for MDR infection; recent ICU stay > 1 week, corticosteroid use, organ transplantation, and baseline pulmonary or hepatic disease further increase risk. 2
• Patients in septic shock require broad‑spectrum combination therapy that covers all likely pathogens. 3

Impact of Inappropriate Initial Therapy

• Inappropriate empiric therapy in critically ill patients markedly increases mortality and is a key modifiable risk factor. [2][3]

Pharmacokinetic/Pharmacodynamic (PK‑PD) Optimization

• Optimize dosing regimens to achieve PK‑PD targets in ICU patients, who often have altered drug clearance due to sepsis, fluid resuscitation, and organ dysfunction. 1

Daily Reassessment and De‑Escalation

• Perform a formal reassessment of antimicrobial therapy on days 2–3; de‑escalate to a narrower spectrum when culture susceptibilities permit. This practice is linked to lower ICU mortality. 2
• Continue daily evaluation of (a) appropriateness of the current regimen, (b) need for ongoing therapy, and (c) opportunities to narrow spectrum. 1
• Discontinue antibiotics entirely when cultures are negative and the patient shows clear clinical improvement, without waiting for normalization of laboratory markers.

Treatment Duration Recommendations (with Adequate Source Control)

• Procalcitonin levels can be used to guide the timing of therapy cessation in critically ill patients. 1

Monitoring, Feedback, and Consumption Metrics

• Track antibiotic consumption (days of therapy per 1,000 patient‑days) and provide feedback to prescribers every 3–6 months together with resistance surveillance and outcome data. [4][1]
• Monitor rates of Clostridioides difficile infection as a quality metric. 2

Invasive Candidiasis Management

• Invasive candidiasis carries an overall mortality of 20–49 % (attributable mortality ≈ 15 %). 1
• Empiric antifungal therapy is justified in (a) patients with septic shock from community‑acquired infections and (b) those with postoperative infections. 3

Implementation Tools and Organizational Strategies

• Develop a local antibiotic policy that includes evidence‑based treatment algorithms, local resistance data, a limited formulary of preferred agents, and mandatory multidisciplinary prescriber review. 4
• Employ computer‑assisted order entry with decision‑support, involve non‑physician healthcare providers, and use therapeutic drug monitoring to reinforce stewardship. 3
• Multifaceted interventions (education, audit‑feedback, decision‑support) are more effective than passive or didactic programs alone. 3

All facts are derived from peer‑reviewed sources; citation IDs correspond to the original references.

Antibiotic Stewardship in the ICU

Core Principles

• The American College of Critical Care Medicine and the Infectious Diseases Society of America recommend implementing a structured antibiotic stewardship program in the ICU, centered on administering broad-spectrum antibiotics within 1 hour for septic patients, performing prospective audit and feedback by infectious disease specialists and pharmacists, de-escalating therapy based on culture results by day 2-3, and limiting treatment duration to 4-7 days for most infections with adequate source control 5, 6, 7
• Administer intravenous antibiotics within the first hour of recognizing sepsis or septic shock, as each hour of delay increases mortality, according to the Surviving Sepsis Campaign 5, 8
• Obtain blood cultures and appropriate specimens before antibiotics, but never delay administration for culture collection, as recommended by the Infectious Diseases Society of America 5, 6

Stewardship Team Structure

• The Society for Healthcare Epidemiology of America recommends that an infectious disease physician with stewardship training leads the program, and a clinical pharmacist with infectious disease expertise performs daily interventions 9, 7, 10
• ICU intensivists serve as frontline champions implementing protocols, and microbiologists provide real-time susceptibility data and resistance surveillance 11, 7

De-escalation Protocol

• De-escalate therapy based on culture results by day 2-3, and narrow spectrum if susceptibilities allow, as recommended by the Infectious Diseases Society of America 5, 6
• Stop antibiotics entirely if cultures are negative and clinical improvement is evident, recognizing that ICU cultures may represent contamination, according to the American College of Critical Care Medicine 5, 6

Duration of Therapy

• The Infectious Diseases Society of America recommends stopping antibiotics earlier, with 4-5 days being sufficient for complicated intra-abdominal infections with adequate source control 12
• Do not wait for normalization of white blood cell count or fever resolution if source control is adequate and clinical trajectory is improving, as recommended by the Society for Healthcare Epidemiology of America 12

Monitoring Program Effectiveness

• Track metrics monthly, including days of therapy per 1000 patient-days, proportion of patients de-escalated by day 3, time from culture result to antibiotic modification, rates of Clostridioides difficile infection, and ICU-specific resistance patterns for key pathogens, as recommended by the Centers for Disease Control and Prevention 11, 7, 10